Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) protein. HER2 is overexpressed in certain types of cancer, particularly breast cancer, and is associated with more aggressive tumor behavior and poor prognosis. Trastuzumab works by binding to HER2 receptors on cancer cells, inhibiting their growth and promoting their destruction by the immune system. Research in the area of trastuzumab focuses on its efficacy in treating HER2-positive cancers, as well as exploring ways to improve its effectiveness and reduce potential side effects. Clinical trials are ongoing to investigate the use of trastuzumab in combination with other cancer treatments, such as chemotherapy or targeted therapy, in various types of cancer. Additionally, researchers are studying biomarkers and predictive factors that can help identify patients who are most likely to benefit from trastuzumab therapy.